Is NMNH legal in Australia?

Raises NAD in cells and mouse tissue faster and higher than NMN, through a pathway that needs neither NRK nor NAMPT. In the same experiments it inhibited glycolysis and the TCA cycle, induced cell cycle arrest and suppressed cell growth in vitro, and no human has been given it in a published trial.

NMNH is the reduced form of NMN and it is the most interesting molecule in this batch, for reasons that cut in both directions. Two groups synthesised it independently and published within weeks of each other in 2021.

Mechanism: NMNH is adenylylated directly by NMNAT enzymes to NADH, which then enters the NAD pool. This bypasses NAMPT, the rate-limiting salvage enzyme that nicotinamide depends on, and also bypasses the NRK kinases that NR depends on, which is why it outperforms both in cells.

Regulatory history: Not an approved drug and not an established dietary ingredient in the United States. Unlike NMN, which has a documented and contested regulatory history, NMNH has no FDA determination of any kind because it has not been the subject of one.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for NMNH at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.